RIBOMUNIL

Active material: bacterial ribosomes, tytrovannыe to 70% ribonucleic acid
When ATH: J07AX
CCF: The immunostimulatory preparation of bacterial origin
ICD-10 codes (testimony): H66, J15, J31, J32, J35.0, J37, J42, J45
When CSF: 12.05.08.02
Manufacturer: PIERRE FABRE MEDICAMENT PRODUCTION (France)

Pharmaceutical form, composition and packaging

Pills round, lenticular, white or nearly white, without smell.

Excipients: silicon, magnesium stearate, sorbitol.

12 PC. – blisters (1) – packs cardboard.

Pills round, lenticular, white or nearly white, without smell.

Excipients: silicon, magnesium stearate, sorbitol.

4 PC. – blisters (1) – packs cardboard.

Granules for oral solution white, without smell.

Excipients: polyvidone, D-mannitol.

Bags of laminated paper (4) – packs cardboard.
Bags made of aluminum foil (4) – packs cardboard.
Plastic Bags (4) – packs cardboard.

Pharmacological action

The immunomodulator of bacterial origin. Ribomunil a ribosomal-proteoglycan complex, which includes the most common pathogens of upper respiratory tract and respiratory tract.

Included in the preparation of the ribosome containing antigens, identical surface antigens of bacteria, and when ingested, cause the formation of specific antibodies to these pathogens (effect of the vaccine). Membrane proteoglycans stimulate non-specific immunity, which is manifested in enhancing phagocytic activity of macrophages and polynuclear leukocytes, increase nonspecific resistance factors. The drug stimulates the function of T- and B-lymphocytes, production of serum and secretory immunoglobulin IgA type, Interleukin-1, and alpha- and gamma-interferon. This explains Ribomunyl preventive effect against respiratory viral infections.

Application Ribomunyl complex therapy can improve efficiency and reduce the duration of treatment, significantly reduce the need for antibiotics, bronchospasmolytics, increase the period of remission.

Pharmacokinetics

Data on the pharmacokinetics Ribomunil not provided.

Testimony

- Prevention and treatment of recurrent infections of upper respiratory tract (otitis, rhinitis, sinusitis, pharyngitis, laringit, sore throat) in patients over 6 months;

- Prevention and treatment of recurrent respiratory tract infections (chronic bronchitis, tracheitis, pneumonia, infektsionnozavisimaya asthma) in patients over 6 months;

- Prevention of recurrent infections in patients at risk (frequently and chronically ill, before the start of the autumn-winter season, especially in environmentally sensitive areas, patients with chronic diseases of upper respiratory tract, chronic bronchitis, asthma, incl. older children 6 months and the elderly).

Dosage regimen

Adults and children over 6 Months drug prescribed 1 time / day in the morning on an empty stomach.

Single dose (regardless of age) is 3 tab. by 0.25 mg (from 1/3 single dose), or 1 tab. by 0.75 mg (single dose), or pellets 1 bag, pre-dissolved boiled water at room temperature.

In the first month of treatment and / or prophylactic Ribomunil taken daily first 4 the day each week for 3 weeks. In the following 2-5 Months – first 4 day of each month.

Young children are encouraged to nominate a preparation in the form of pellets.

Side effect

There is rarely.

From the digestive system: hypersalivation at the beginning of treatment, nausea, vomiting, diarrhea.

Allergic reactions: hives, angioedema.

Contraindications

- Autoimmune diseases;

- Hypersensitivity to the drug.

Pregnancy and lactation

Special studies on the safety and efficacy of Ribomunyl during pregnancy and lactation has not been.

Application Ribomunyl during pregnancy and lactation (breast-feeding) It is possible only after the evaluation of the anticipated benefits to the mother and the potential risk to the fetus and child.

Cautions

Patients should be warned of the possibility of a transient increase in body temperature 2-3 day, which it is a manifestation of the therapeutic effect of the drug and does not require, usually, discontinuation of treatment. Rising temperatures can sometimes be accompanied by a minor and transient symptoms of upper respiratory tract infections.

Overdose

Currently, cases of drug overdose were reported Ribomunil.

Drug Interactions

So far, clinically significant drug interactions are not described drug Ribomunil.

Ribomunil can be combined with other drugs (antibiotics, broncholytics, anti-inflammatory drugs).

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children and transport (all types of covered transport) at a temperature from 15 ° to 25 ° C. Shelf life of the granules and tablets 1 dose – 3 year. Shelf life tablets 1/3 dose – 5 years.